Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Sochacki AL, Fischer MA, Savona MR.

Onco Targets Ther. 2016 Apr 15;9:2273-86. doi: 10.2147/OTT.S83868. eCollection 2016. Review.

2.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Ditschkowski M, Elmaagacli AH, Trenschel R, Gromke T, Steckel NK, Koldehoff M, Beelen DW.

Haematologica. 2012 Oct;97(10):1574-81. doi: 10.3324/haematol.2011.061168. Epub 2012 Apr 4.

3.

Factors affecting prognosis in myelofibrosis.

Onida F.

F1000 Med Rep. 2009 Jul 8;1. pii: 55. doi: 10.3410/M1-55.

4.

Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.

Verstovsek S.

Clin Cancer Res. 2010 Apr 1;16(7):1988-96. doi: 10.1158/1078-0432.CCR-09-2836. Epub 2010 Mar 9. Review.

5.

Outcome of transplantation for myelofibrosis.

Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M.

Biol Blood Marrow Transplant. 2010 Mar;16(3):358-67. doi: 10.1016/j.bbmt.2009.10.025. Epub 2009 Oct 30.

6.

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S.

J Clin Oncol. 2009 Nov 20;27(33):5587-93. doi: 10.1200/JCO.2009.22.8833. Epub 2009 Sep 28.

7.

Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.

Abu-Hilal M, Tawaker J.

World J Gastroenterol. 2009 Jul 7;15(25):3128-33.

8.

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

Zang DY, Deeg HJ.

Curr Opin Hematol. 2009 Mar;16(2):140-6. doi: 10.1097/MOH.0b013e3283257ab2. Review.

9.

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S.

Blood. 2009 Apr 30;113(18):4171-8. doi: 10.1182/blood-2008-09-178541. Epub 2009 Jan 8.

Supplemental Content

Support Center